Microdosing Semaglutide: A Gentler Entry Into GLP-1 Therapy With Fewer Side Effects
GLP-1 receptor agonist therapy has transformed obesity medicine — but it comes with a predictable set of side effects that cause a significant proportion of patients to abandon treatment before reaching effective doses. Nausea, vomiting, and diarrhea are the most common, typically most pronounced in the first 4–8 weeks as doses are escalated. For some patients, a slower, more gradual introduction is what makes the difference between completing titration and stopping early.
Microdose semaglutide + B12 is a protocol that starts below standard initial doses, allowing the GI tract and CNS appetite centers to adapt before further increases.
Why Side Effects Occur — and Why Lower Doses Help
The GI side effects of semaglutide — nausea, reduced gastric motility, delayed gastric emptying — are direct pharmacological effects of GLP-1 receptor activation in the gut. They are dose-dependent and receptor saturation-dependent: they are most severe when a patient first encounters the medication and when doses are escalated rapidly.
By starting at sub-therapeutic doses (0.125–0.25mg weekly), microdose protocols allow GLP-1 receptor expression in the gut to adapt gradually. The clinical analogy is similar to the titration protocols used for other receptor-modulating medications: the body adapts when changes are incremental.
The Role of B12 in the Formula
Vitamin B12 serves multiple purposes in the compounded formula:
Counteracts the potential B12 depletion associated with weight loss and dietary restriction
Supports energy production during caloric deficit
Provides the injection vehicle as part of a combination preparation
Who Microdose Protocols Are For
Microdose semaglutide + B12 is particularly appropriate for:
Patients who have previously stopped GLP-1 therapy due to nausea or GI intolerance
Patients with GI sensitivity, IBS, or a history of medication-related GI side effects
Patients who prefer a conservative, step-wise approach to new medications
Patients who are very close to their target weight and want modest, sustainable appetite support
Clinical Expectations
Weight loss on microdose protocols is typically slower than standard-dose semaglutide but achieves the same mechanism of action at lower receptor saturation levels. Some patients find that microdoses provide meaningful appetite suppression and are maintained at that dose level long-term. Others titrate to standard doses over an extended period with minimal side effects.
Microdose semaglutide is a compounded prescription medication. Not everyone qualifies. A licensed provider determines dosing based on individual health profile and prior treatment history.
